Cagrilintide

Cagrilintide (AM833), commonly called “Cagri,” is an investigational long-acting peptide developed by Novo Nordisk to support weight management through the body’s natural appetite-regulating pathways. It is a modified analogue of amylin, a hormone released alongside insulin by the pancreas after eating. Unlike GLP-1 medications that primarily activate incretin receptors, cagrilintide targets amylin and calcitonin receptors involved in hunger, fullness, and food intake. Its molecular structure has been engineered to resist degradation and remain active for approximately one week, allowing once-weekly administration in clinical trials.

Human studies have demonstrated significant weight reduction with cagrilintide alone, while combining it with the GLP-1 medication semaglutide produces even greater effects. This combination, known as CagriSema, has achieved average weight loss exceeding 20% in large Phase 3 obesity trials, highlighting the potential benefits of targeting multiple appetite-regulating pathways. Researchers are also investigating its effects on glucose regulation, cardiometabolic health, and long-term weight maintenance. Although clinical evidence is substantial, cagrilintide remains investigational and is not currently FDA-approved as a standalone medication or combination treatment.

Cagrilintide mimics amylin, a naturally occurring hormone that helps the brain recognize when enough food has been consumed. Its long-acting structure allows sustained signaling through receptors involved in appetite and metabolic regulation.

1. Amylin Receptor Activation: Increasing Fullness

• Amylin is normally released by pancreatic beta cells alongside insulin after eating.
• Cagrilintide activates amylin receptor pathways involved in reducing food intake.
• These signals help the brain recognize satiety, potentially allowing smaller meals to feel more satisfying.

2. Brainstem Signaling: Regulating Hunger

• Cagrilintide influences appetite-related pathways in the area postrema and nucleus of the solitary tract.
• These brainstem regions help process signals related to food intake, gastrointestinal activity, and fullness.
• Experimental research suggests additional interactions with broader appetite-regulating neural circuits.

3. Delayed Gastric Emptying

• Amylin signaling can slow the movement of food from the stomach into the small intestine.
• This may contribute to longer-lasting fullness after meals.
• Delayed gastric emptying can also contribute to nausea, bloating, and gastrointestinal discomfort.

4. Glucagon and Glucose Regulation

• Amylin normally helps regulate inappropriate glucagon release after meals.
• Glucagon influences glucose production by the liver.
• Cagrilintide's potential effects on post-meal glucose regulation are being investigated, particularly in combination with GLP-1 therapy.

5. Long-Acting Molecular Design

• Cagrilintide contains structural modifications designed to improve peptide stability.
• A fatty-acid-based modification promotes binding to albumin in the bloodstream.
• Albumin binding helps extend circulation time and supports once-weekly administration.

6. Complementary Signaling With GLP-1

• Semaglutide activates GLP-1 receptors involved in appetite, insulin secretion, and glucose regulation.
• Cagrilintide activates amylin-related pathways that also influence satiety and food intake.
• Combining these mechanisms has produced greater weight reduction than either compound alone in clinical trials.

The Key Difference: Cagrilintide is not primarily a stimulant or direct fat-burning peptide. Its weight-loss effects are driven largely by changes in appetite, fullness, and energy intake. Both cagrilintide and GLP-1 medications influence overlapping brain networks, but they activate different receptor systems.

Cagrilintide has attracted substantial scientific interest because it targets appetite regulation through a hormonal pathway different from conventional GLP-1 medications, creating opportunities for both standalone treatment and combination therapy.

• Significant Weight Reduction: Human clinical trials demonstrate meaningful weight loss with cagrilintide alone.
• Appetite Suppression: Amylin receptor activation influences hunger signals and overall food consumption.
• Increased Satiety: Cagrilintide may help people feel satisfied after consuming smaller meals.
• Combination Therapy: Adding cagrilintide to semaglutide has produced greater average weight reduction than either treatment alone.
• Type 2 Diabetes: Clinical studies are evaluating improvements in body weight and blood glucose when combined with GLP-1 therapy.
• Cardiometabolic Health: Researchers are investigating changes in blood pressure, waist circumference, and other obesity-related risk factors.
• Alternative Appetite Pathways: Amylin-based medications may provide another treatment approach for individuals who need alternatives to GLP-1 receptor agonists.
• Long-Term Weight Management: Ongoing studies are investigating maintenance, dose flexibility, and treatment durability.

Research Limitation: Although weight-loss effectiveness is supported by substantial human evidence, long-term cardiovascular outcomes, optimal treatment duration, and comparative effectiveness across different patient populations continue to be investigated.

Large human clinical trials have demonstrated significant weight reduction with cagrilintide, particularly when combined with semaglutide. Several studies also reported improvements in obesity-related metabolic measurements.

• Cagrilintide Monotherapy: A Phase 2 trial reported average weight reductions ranging from 6.0% to 10.8% after 26 weeks across studied doses.
• Longer-Term Monotherapy: The Phase 3 REDEFINE 1 trial demonstrated approximately 11.5% average weight reduction with cagrilintide 2.4 mg alone after 68 weeks.
• CagriSema Combination Therapy: REDEFINE 1 demonstrated 20.4% average weight loss after 68 weeks, compared with 3.0% for placebo.
• Greater Loss With Full Treatment Adherence: REDEFINE 1 estimated 22.7% average weight reduction under its trial-product analysis.
• Type 2 Diabetes: REDEFINE 2 reported 13.7% average weight loss with CagriSema versus 3.4% for placebo after 68 weeks.
• Improved Glucose Regulation: In REDEFINE 2, 73.5% of participants receiving CagriSema achieved an HbA1c of 6.5% or lower, compared with 15.9% receiving placebo.
• Blood Pressure: A REDEFINE 1 analysis reported greater reductions in systolic and diastolic blood pressure with combination treatment than with placebo.
• Additional Weight-Loss Targets: Clinical trials demonstrated increased proportions of participants achieving 15%, 20%, and 25% or greater weight reduction.

Notable Phase 2 Finding: After 26 weeks, cagrilintide 4.5 mg produced approximately 10.8% average weight loss compared with 3.0% for placebo and 9.0% with liraglutide 3 mg.

Notable Phase 3 Finding: In REDEFINE 1, participants receiving CagriSema achieved 20.4% average weight loss at 68 weeks using the treatment-policy analysis. The 22.7% figure represents a different analysis estimating outcomes with treatment adherence.

Head-to-Head Research: In the 84-week REDEFINE 4 trial, CagriSema achieved 23.0% estimated weight loss compared with 25.5% for tirzepatide 15 mg. The study did not meet its primary endpoint of demonstrating noninferiority to tirzepatide.

Research Perspective: Cagrilintide has demonstrated meaningful weight-loss effectiveness in humans, but results vary by dose, treatment duration, population, and whether it is combined with semaglutide. Combination results should not be attributed to cagrilintide alone, and individual outcomes may differ substantially from clinical trial averages.

Cagrilintide has been investigated primarily as a once-weekly subcutaneous injection. Clinical studies used gradual dose escalation to improve tolerability, particularly because nausea and other gastrointestinal symptoms can increase with higher doses. Community research discussions describe additional dosing patterns, but these have not been validated through controlled clinical trials.

Published Clinical and Community-Reported Dosing

Clinical Trial Titration Schedule: REDEFINE Program

Note: In the studied CagriSema regimen, semaglutide was escalated alongside cagrilintide using the same numerical dose steps. This table documents the clinical trial protocol and is not an individualized dosing recommendation.

Administration Considerations:

• Subcutaneous Administration: The principal route evaluated in human trials.
• Frequency: Once-weekly administration is supported by clinical research. More frequent community schedules have not demonstrated superior outcomes.
• Gradual Escalation: Clinical studies increased doses over several weeks, with flexibility to delay increases or reduce doses when tolerability was poor.
• Half-Life: Approximately 160–195 hours, supporting sustained activity between weekly administrations.
• Plateaus: Community recommendations to increase doses after a specific number of days without weight loss are not validated clinical protocols.
• Missed Doses: No FDA-approved missed-dose or restarting instructions exist for cagrilintide.
• Reconstitution: No FDA-approved consumer formulation or validated home-mixing procedure exists. The peptide's stability depends on formulation conditions, and neutral-pH solutions cannot automatically be assumed suitable.

Important Distinction: Community-reported quantities and divided dosing schedules are not interchangeable with published clinical trial protocols. Because cagrilintide remains active for approximately one week, changing administration frequency may alter cumulative exposure.

Research Perspective: The reported community amounts are included for educational comparison rather than as treatment recommendations. Clinical trial dosing was conducted with pharmaceutical formulations and medical monitoring, conditions that cannot be assumed for unregulated research-market products.

Cagrilintide has primarily been studied through continuous weekly administration rather than short treatment cycles. Because obesity is often a chronic condition, researchers are investigating long-term weight management and what happens when treatment is modified or discontinued.

• Phase 2 Monotherapy Research: Studied once-weekly treatment for 26 weeks.
• REDEFINE 1 and 2: Evaluated continuous treatment over 68 weeks.
• REDEFINE 4: Investigated CagriSema and tirzepatide over 84 weeks.
• Community Short Cycles: Eight- to sixteen-week periods are discussed informally, but these are not established clinical protocols.
• Community Washout Periods: Four- to eight-week breaks are sometimes proposed without evidence that they improve safety or effectiveness.
• Long-Term Maintenance: Research continues into lower-dose maintenance strategies, dose reduction, and sustained weight management.
• Discontinuation: Increased hunger and weight regain may occur when effective appetite-regulating treatment is stopped.

Research Consideration: Clinical studies have not established that cycling cagrilintide prevents receptor tolerance or produces better weight-loss outcomes than continuous therapy.

Important Limitation: Short community cycles should not be confused with the substantially longer treatment periods evaluated in clinical trials. Long-term treatment decisions depend on effectiveness, tolerability, and individual medical considerations.

Cagrilintide has generated considerable interest in combination therapy because amylin signaling complements several other metabolic pathways. The strongest evidence supports its combination with semaglutide, while most other experimental stacks remain unvalidated.

Research Perspective: Cagrilintide combined with semaglutide has demonstrated greater weight reduction than either compound alone in clinical trials. However, these findings cannot be extended automatically to combinations with tirzepatide, retatrutide, or other investigational peptides.

Important Distinction: More appetite suppression is not necessarily better. Combining multiple potent metabolic therapies may increase nausea, inadequate nutritional intake, dehydration, and other adverse effects.

Cagrilintide's most common adverse effects are gastrointestinal and are associated with its effects on appetite, fullness, and digestive function. Clinical studies generally reported that gastrointestinal symptoms were mild to moderate and often improved over time, although some participants discontinued treatment because of adverse effects.

Notable Clinical Finding: In REDEFINE 1, gastrointestinal adverse events occurred in approximately 79.6% of participants receiving CagriSema compared with 39.9% receiving placebo. Most were mild to moderate and transient.

Monotherapy Safety Finding: In the 26-week Phase 2 cagrilintide study, gastrointestinal adverse events occurred in approximately 41–63% of cagrilintide recipients across dose groups, compared with approximately 32% receiving placebo.

Important Safety Distinction: Adverse-event rates from CagriSema reflect exposure to both cagrilintide and semaglutide and should not be attributed entirely to cagrilintide.

Research Perspective: Careful clinical dose escalation and nutritional monitoring were important parts of the clinical studies. The safety of unregulated formulations, modified administration schedules, or experimental combinations remains uncertain.

No FDA-approved contraindication profile exists for cagrilintide because it remains investigational. Published clinical trials provide meaningful safety information, but several medical conditions and treatment combinations require additional consideration.

• Pregnancy and Breastfeeding: Adequate reproductive, fetal-development, and lactation safety data are unavailable.
• Severe Gastrointestinal Disease: Individuals with significant gastric motility disorders may experience worsening symptoms from treatments affecting gastric emptying.
• History of Pancreatitis: The risk profile in individuals with previous pancreatic inflammation remains incompletely established.
• Gallbladder Disease: Significant weight loss and gastrointestinal hormone therapies may be associated with gallbladder complications.
• Diabetes: Changes in food intake and glucose regulation may require adjustment of existing diabetes medications.
• Kidney Disease: Persistent vomiting, diarrhea, or reduced fluid intake may contribute to dehydration-related kidney injury.
• Malnutrition / Eating Disorders: Powerful appetite suppression may worsen inadequate nutrition or problematic restrictive eating.
• Concurrent GLP-1 Medications: Combining cagrilintide with other incretin-based treatments outside controlled trials has not been established as safe.
• Other Amylin Agonists: Concurrent pramlintide or similar compounds may duplicate biological activity and increase adverse effects.
• Oral Medications: Changes in gastric emptying may affect the timing of absorption of some medications. A universal one-hour separation rule has not been validated for cagrilintide.
• Unregulated Products: Research-market formulations may differ in concentration, purity, sterility, chemical stability, or active ingredients.

Regulatory Caution: Cagrilintide and CagriSema are not FDA-approved as of October 2026. The FDA has stated that cagrilintide cannot legally be used in drug compounding under federal law.

Important Distinction: Precautions associated with semaglutide-containing CagriSema should not automatically be presented as proven cagrilintide-specific contraindications. The individual compound and its combination require separate safety assessments.

Cagrilintide research has focused on body weight, appetite regulation, glucose metabolism, cardiovascular risk factors, and treatment tolerability. Because substantial weight reduction can affect body composition and nutrition, monitoring should consider more than changes on the scale alone.

Research Consideration: Weight reduction alone does not distinguish loss of body fat from loss of lean tissue. Body composition measurements, adequate nutrition, and functional assessments may provide a more complete picture of treatment outcomes.

Important Limitation: Anti-drug antibody measurements are research tools rather than routine clinical tests. No individual biomarker establishes the overall safety or effectiveness of cagrilintide.